AstraZeneca announced in May 2026 that its drug Ultomiris significantly reduced urine protein levels in patients with IgA ...

FRANKFURT, April 21 (Reuters) - AstraZeneca's CEO told daily Handelsblatt on Tuesday that Germany risks missing out on new ...

AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has served up a third phase 3 win this year, offering ...

Speaking to German newspaper Handelsblatt, CEO Pascal Soriot said proposed cost-cutting measures in the country’s healthcare ...

GSK, by contrast, faces a patent cliff of its own. Dolutegravir, the backbone of its HIV franchise, loses US exclusivity from ...

A federal appellate court has handed down the first appellate-level decision addressing the merits of drug manufacturers’ challenges to the Inflation Reduction Act of 2022's (IRA) Medicare Drug ...

After another swing and a miss for AstraZeneca's Fasenra in chronic obstructive pulmonary disease (COPD), the company is pivoting to other options in its portfolio that might have potential to treat ...

Wondering if AstraZeneca at £152.30 is still offering value after a strong run, or if most of the easy gains are already ...

AstraZeneca’s Ultomiris met its first co-primary endpoint in a Phase III trial for IgA nephropathy, significantly reducing urine protein levels by week 34. The result supports the drug’s potential as ...